Validation of Dual Energy X-ray Absorptiometry for longitudinal quantification of tumor burden in a murine model of pancreatic ductal adenocarcinoma.

Autor:	Sechrist ZR; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States.; Department of Surgical Oncology, University of Rochester Medical Center, Rochester, New York, United States.; Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, United States., Lee G; Department of Biology, University of Rochester, Rochester, New York, United States., Schwarz EM; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States.; Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, United States., Cole CL; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States.; Department of Surgical Oncology, University of Rochester Medical Center, Rochester, New York, United States.; Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, United States.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2023 Sep 19. Date of Electronic Publication: 2023 Sep 19.
DOI:	10.1101/2023.09.17.558153
Abstrakt:	Noninvasive imaging is central to preclinical, in vivo models of pancreatic ductal adenocarcinoma (PDAC). While bioluminescent imaging (BLI) is a gold standard, its signal is dependent on the metabolic activity of tumor cells. In contrast, dual energy X-ray absorptiometry (DEXA) is a direct measure of body composition. Thus, we aimed to assess its potential for longitudinal quantification of tumor burden versus BLI. We utilized the KCKO murine model of PDAC and subjected tumor-bearing (n = 20) and non-tumor control (NTC) (n = 10) animals to weekly BLI and DEXA measurements for up to 10 weeks. While BLI detected tumors at 1-week, it failed to detect tumor growth, displayed a decreasing trend overtime (slope = -9.0×10 8 ; p = 0.0028), and terminal signal did not correlate with ex vivo tumor mass (r = 0.01853; p = 0.6286). In contrast, DEXA did not detect elevated changes in abdominal cavity lean mass until week 2 post inoculation and tumors were not visible until week 3, but successfully quantified a tumor growth trend (slope = 0.7322; p<0.0001), and strongly correlated with final tumor mass (r = 0.9351; p<0.0001). These findings support the use of BLI for initial tumor engraftment and persistence but demonstrate the superiority of DEXA for longitudinal tumor burden studies. As tumor detection by DEXA is not restricted to luciferase expressing models, future studies to assess its value in various cancer models and as an in vivo outcome measure of treatment efficacy are warranted. Competing Interests: Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu